IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0636291
(2006-12-08)
|
등록번호 |
US-8357394
(2013-01-22)
|
발명자
/ 주소 |
- Flanner, Henry H.
- Guttendorf, Robert J.
- Clausen, Susan P.
- Treacy, Donald
- Burnside, Beth A.
|
출원인 / 주소 |
|
인용정보 |
피인용 횟수 :
0 인용 특허 :
272 |
초록
▼
Disclosed are once-a-day penicillin-type antibiotic products comprising at least one modified release dosage form comprising penicillin-type antibiotics and pharmaceutically acceptable carriers, which compositions provide TMIC90 in the serum for at least 5 hours (preferably for at least five consecu
Disclosed are once-a-day penicillin-type antibiotic products comprising at least one modified release dosage form comprising penicillin-type antibiotics and pharmaceutically acceptable carriers, which compositions provide TMIC90 in the serum for at least 5 hours (preferably for at least five consecutive hours), within a 24-hour dosing interval, for a given bacterial pathogen's MIC90, while providing a total dosage of the penicillin-type antibiotic for a 24-hour dosing interval.
대표청구항
▼
1. A once-a-day amoxicillin antibiotic product comprising; first, second, and third amoxicillin antibiotic dosage forms, each of said amoxicillin antibiotic dosage forms comprising at least one amoxicillin antibiotic and a pharmaceutically acceptable carrier, said first amoxicillin antibiotic dosage
1. A once-a-day amoxicillin antibiotic product comprising; first, second, and third amoxicillin antibiotic dosage forms, each of said amoxicillin antibiotic dosage forms comprising at least one amoxicillin antibiotic and a pharmaceutically acceptable carrier, said first amoxicillin antibiotic dosage form being, an immediate release dosage form, said second and third amoxicillin antibiotic dosage forms being delayed release: dosage forms, wherein said second amoxicillin antibiotic dosage form comprises amoxicillin coated with a methacrylic acid copolymer dispersion and said third amoxicillin antibiotic dosage form comprises amoxicillin coated with a first layer of a methacrylic acid copolymer dispersion and a second layer of hypromellose acetate succinate, and wherein each of said first, second, and third amoxicillin antibiotic dosage forms initiates release at different times, Cmax of the total amoxicillin antibiotic released from said amoxicillin antibiotic product is achieved in less that about 12 hours from administration; wherein said product contains the total dosage of amoxicillin, for a 24-hour dosing interval. 2. The product of claim 1, wherein said total dosage of amoxicillin is from about 775 mg to about 1550 mg. 3. The product of claim 1, wherein said first amoxicillin antibiotic dosage form comprises 10-90% of the product, wherein said second amoxicillin antibiotic dosage form comprises 10-90% of the product, and wherein said third amoxicillin antibiotic dosage form comprises 10-90% of the product. 4. The product of claim 3, wherein said first amoxicillin antibiotic dosage form comprises 45% of the product, wherein said, second amoxicillin antibiotic dosage form comprises 30% of the, product, and wherein said third amoxicillin antibiotic dosage form comprises 25% of the product. 5. The product of claim 1, wherein when the product is administered to a patient or subject in need thereof, the product provides a concentration of amoxicillin in the serum at or above the MIC90 for an infecting bacterial pathogen for at least 5 hours within a 24-hour dosing interval. 6. The product of claim 1, wherein said second and third amoxicillin antibiotic dosage forms further comprise microcrystalline cellulose, povidone, and polyoxyl 35 castor oil. 7. The product of claim 1, wherein amoxicillin is the only antibiotic present in the first, second, and third amoxicillin antibiotic dosage forms.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.